RASi for Preventing Postoperative Recurrence of Stage II/III Colon Cancer

Previous studies have shown that renin-angiotensin system inhibitors (RASi) may reduce postoperative recurrence and metastases of colorectal cancer. However, the relevant clinical evidences were low level and controversial. This study retrospectively collect patients with hypertension and stage II/III colon cancer after radical resection, and compare the patients with vs. without RASi in terms of long-term oncological outcomes, to study the inhibitory effect of RASi on recurrence and metastasis.

Inclusion criteria

• Inferior tumor edge > 15 cm from anal verge;
• Received radical resection of primary tumor;
• Pathological proved stage II or stage III adenocarcinoma;
• No evidence of distant metastases at time of surgery (including pelvis, peritoneum, liver, lung, brain, bone, distant lymph node, etc), according to ultrasound, CT, MRI, PET-CT, intraoperative exploration, etc;
• Combined with hypertension at time of surgery;
• No other malignancies in medical history except adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri;
• Informed consent.

Exclusion criteria

• Emergency surgery for acute intestinal obstruction, bleeding, perforation, etc;
• Multiple primary colorectal cancer;
• Hereditary colorectal cancer (familial adenomatosis polyposis, Lynch Syndrome, etc.);
• Co-existent inflammatory bowel disease;
• Pregnancy or lactation;
• Received any of preoperative anti-cancer treatment.